Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Multicenter Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
Conditions
Interventions
Anlotinib hydrochloride capsule
Carboplatin injection
+2 more
Locations
59
China
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Anhui Chest Hospital
Hefei, Anhui, China
Yijishan Hospital of Wannan Medical College
Wuhu, Anhui, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
The Sixth Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Start Date
August 8, 2019
Primary Completion Date
June 1, 2021
Completion Date
December 31, 2021
Last Updated
June 19, 2020
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions